drugset
drugset / Trial / NCT05814731

Study on the Efficacy and Safety of MA-BUCY2 Conditioning in High-risk AML Patients Underwent Haplo-HSCT

NCT05814731 ↗

Unknown 264 enrolled First Affiliated Hospital Xi'an Jiaotong University
RandomizedParallel-groupOpen-labelTreatment

Summary

According to the 2022 ELN guidelines patients with high-risk acute myeloid leukemia were randomly divided into MA-BUCY2 conditioning group and BuCy2 conditioning group，to evaluate the efficacy and safety of two conditioning regimens in haploidentical hematopoietic stem cell transplantation.

Timeline

Start
2023-04-15
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitoxantrone Small molecule 20 mg/m2 Intravenous
Background ATG Unknown 2.5 mg/kg —
Background BU Unknown 0.8 mg/kg Intravenous
Background CTX Unknown 1.8 g/kg Intravenous
Background Cytarabine Small molecule 4 g/kg Intravenous
Background Me-CCNU Unknown 250 mg/m2 Oral

Indications

disease related to hematopoietic stem cell transplant